Quality Of Life In Colorectal Cancer Survivors

NCT07427901 | Recruiting

• 3 other identifiers: OIL_CCS_2023ERIDNPVO-0051/20230120-192/2023/6
• Study Type: interventional
• Target: 368
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this study is to identify late adverse effects in colorectal cancer patients that may influence quality of life at 6, 12, and 24 months after oncological treatment. The study aims to assess quality of life in colorectal cancer survivors in relation to psycho-physical-social well-being at different time points and to evaluate the prevalence of late adverse effects and their association with diagnosis and specific oncological treatment.

Conditions

Colorectal Cancer; Colon Cancer; Rectal Cancer

Keywords

Quality of Life; Cancer Survivors; Late Adverse Effects

Outcome Measures

Primary Outcomes (1)

• Quality of Life Score (EORTC QLQ-C30 Global Health Status/QoL Scale)

  Quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30), specifically the Global Health Status/Quality of Life scale (items 29 and 30). Scores will be linearly transformed to a 0 to 100 scale. Higher scores indicate better quality of life.

  6, 12, and 24 months after oncological treatment

Secondary Outcomes (1)

• Colorectal Cancer-Specific Quality of Life (EORTC QLQ-CR29)

  6, 12, and 24 months after oncological treatment

Study Arms (1)

Quality of Life Assessment Group

EXPERIMENTAL

Participants with colorectal cancer after oncological treatment will complete quality of life assessments at 6, 12, and 24 months to identify late adverse effects and evaluate psycho-physical-social well-being.

Other: Quality of Life Assessment

Interventions

Quality of Life Assessment OTHER

Quality of life assessment using questionnaires at 6, 12, and 24 months after oncological treatment.

Quality of Life Assessment Group

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Patients with colorectal cancer (colon or rectal cancer)
• Age 25 to 65 years
• First oncological treatment performed at the Institute of Oncology Ljubljana
• Working-capable patients
• Ability to complete questionnaires
• Ability to provide written informed consent

You may not qualify if:

• Age \< 25 years or \> 65 years
• Patients unable to complete questionnaires
• Patients unable to participate in follow-up assessments
• Patients who do not provide written informed consent

Sponsors & Collaborators

• Institute of Oncology Ljubljana: lead

Study Sites (1)

Institute of Oncology Ljubljana

Ljubljana, 1000, Slovenia

RECRUITING

MeSH Terms

Conditions

Colorectal Neoplasms; Colonic Neoplasms; Rectal Neoplasms

Condition Hierarchy (Ancestors)

Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Rectal Diseases

Central Study Contacts

Klavdija Korošec

CONTACT

+386 31630065; kkorosec@onko-i.si

Neža Gros

CONTACT

ngros@onko-i.si

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: OTHER
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Single-group study evaluating quality of life and late adverse effects in colorectal cancer patients at 6, 12, and 24 months after oncological treatment.

Study Record Dates

• First Submitted: February 5, 2026
• First Posted: February 23, 2026
• Study Start: May 1, 2023
• Primary Completion: January 1, 2024
• Study Completion (Estimated): December 31, 2027
• Last Updated: February 23, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

SL (1)